Stock comparison
ResMed
UFP Technologies
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
UFPT
UFP Technologies
Market cap
$1.77B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | UFPT | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 64C | RMD |
| Benjamin Graham | 75B | 79B | UFPT |
| Philip Fisher | 75B | 64C | RMD |
| Peter Lynch | 58C | 62C | UFPT |
| Joel Greenblatt | 47D | 43D | RMD |
| Charlie Munger | 69B | 50C | RMD |
| Terry Smith | 73B | 52D | RMD |
Side-by-side metrics
| Metric | RMD | UFPT |
|---|---|---|
| Market cap | $30.18B | $1.77B |
| P/E (TTM) | 19.6x | 24.4x |
| EV/EBIT | 17.1x | 19.7x |
| ROIC (TTM) | 19.63% | 12.31% |
| Gross margin | 61.69% | 28.35% |
| Net margin | 27.44% | 11.27% |
| Revenue CAGR 5y | 12.64% | 30.74% |
| EPS CAGR 5y | 30.73% | 43.19% |
| Debt / Equity | 0.1x | 0.4x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $1.77B+94%
- Debt / Equity0.1xvs 0.4x+63%
- Net margin27.44%vs 11.27%+59%
UFPT leads on
- Revenue CAGR 5y30.74%vs 12.64%+59%
- EPS CAGR 5y43.19%vs 30.73%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.